We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04345406
Recruitment Status : Not yet recruiting
First Posted : April 14, 2020
Last Update Posted : April 14, 2020
Information provided by (Responsible Party):
Sherief Abd-Elsalam, Tanta University

Brief Summary:
ACEIs as treatment for COVID19

Condition or disease Intervention/treatment Phase
COVID Drug: ACEIs Drug: Conventional treatment Phase 3

Detailed Description:
ACEIs as suggested treatment for COVID19

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Trial of ACEIs in Treatment of COVID-19
Estimated Study Start Date : April 15, 2020
Estimated Primary Completion Date : December 1, 2029
Estimated Study Completion Date : December 1, 2029

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: ACEIs
ACEIs with conventional treatment for COVID19
Drug: ACEIs
Captopril or enalapril
Other Name: Enalapril, Captopril

Drug: Conventional treatment
Other Name: chloroquine

Experimental: Conventional treatment of COVID19
Conventional treatment of COVID19
Drug: Conventional treatment
Other Name: chloroquine

Primary Outcome Measures :
  1. number of patients with virological cure [ Time Frame: 6 months ]
    number of patients with virological cure

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients infected with covid 19

Exclusion Criteria:

  • allergy or contraindications to the drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04345406

Layout table for location contacts
Contact: Sherief Abd-Elsalam +201147773440 sheriefabdelsalam@yahoo.com

Layout table for location information
Tanta University
Tanta, Egypt, 35111
Sponsors and Collaborators
Tanta University
Layout table for investigator information
Principal Investigator: Sherief Abd-Elsalam, ass. prof. Tanta University Faculty of medicine
Layout table for additonal information
Responsible Party: Sherief Abd-Elsalam, assistant professor of tropical medicine and infectious diseases, Tanta University
ClinicalTrials.gov Identifier: NCT04345406    
Other Study ID Numbers: ACEIS COVID 19
First Posted: April 14, 2020    Key Record Dates
Last Update Posted: April 14, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Antirheumatic Agents
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents